203 related articles for article (PubMed ID: 14618237)
1. Angiotensin AT(1) receptor antagonism normalizes retinal blood flow and acetylcholine-induced vasodilatation in normotensive diabetic rats.
Horio N; Clermont AC; Abiko A; Abiko T; Shoelson BD; Bursell SE; Feener EP
Diabetologia; 2004 Jan; 47(1):113-23. PubMed ID: 14618237
[TBL] [Abstract][Full Text] [Related]
2. Gender-specific regulation of pancreatic islet blood flow, insulin levels and glycaemia in spontaneously diabetic Goto-Kakizaki rats.
Huang Z; Jansson L; Sjöholm A
Clin Sci (Lond); 2008 Jul; 115(1):35-42. PubMed ID: 18205625
[TBL] [Abstract][Full Text] [Related]
3. Protection against oxidative stress in diabetic rats: role of angiotensin AT(1) receptor and beta 1-adrenoceptor antagonism.
Dorenkamp M; Riad A; Stiehl S; Spillmann F; Westermann D; Du J; Pauschinger M; Noutsias M; Adams V; Schultheiss HP; Tschöpe C
Eur J Pharmacol; 2005 Sep; 520(1-3):179-87. PubMed ID: 16139267
[TBL] [Abstract][Full Text] [Related]
4. Specific retinal diacylglycerol and protein kinase C beta isoform modulation mimics abnormal retinal hemodynamics in diabetic rats.
Bursell SE; Takagi C; Clermont AC; Takagi H; Mori F; Ishii H; King GL
Invest Ophthalmol Vis Sci; 1997 Dec; 38(13):2711-20. PubMed ID: 9418723
[TBL] [Abstract][Full Text] [Related]
5. Possible role of VEGF in the progression of kidney disease in streptozotocin (STZ)-induced diabetic rats: effects of an ACE inhibitor and an angiotensin II receptor antagonist.
Kakizawa H; Itoh Y; Imamura S; Matsumoto T; Ishiwata Y; Ono Y; Yamamoto K; Kato T; Hayakawa N; Oda N; Goto Y; Goto Y; Nagasaka A; Senda T; Itoh M
Horm Metab Res; 2004 Jul; 36(7):458-64. PubMed ID: 15305228
[TBL] [Abstract][Full Text] [Related]
6. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor.
Fukuda K; Hirooka K; Mizote M; Nakamura T; Itano T; Shiraga F
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3629-38. PubMed ID: 20164447
[TBL] [Abstract][Full Text] [Related]
7. Racial differences in renal vascular response to angiotensin blockade with captopril or candesartan.
Forman JP; Price DA; Stevanovic R; Fisher ND
J Hypertens; 2007 Apr; 25(4):877-82. PubMed ID: 17351382
[TBL] [Abstract][Full Text] [Related]
8. Regulation of retinal hemodynamics in diabetic rats by increased expression and action of endothelin-1.
Takagi C; Bursell SE; Lin YW; Takagi H; Duh E; Jiang Z; Clermont AC; King GL
Invest Ophthalmol Vis Sci; 1996 Nov; 37(12):2504-18. PubMed ID: 8933767
[TBL] [Abstract][Full Text] [Related]
9. The angiotensin II receptor antagonist candesartan cilexetil (TCV-116) ameliorates retinal disorders in rats.
Nagisa Y; Shintani A; Nakagawa S
Diabetologia; 2001 Jul; 44(7):883-8. PubMed ID: 11508274
[TBL] [Abstract][Full Text] [Related]
10. Angiotensin II receptor antagonist improves age-related endothelial dysfunction.
Kansui Y; Fujii K; Goto K; Abe I; Iida M
J Hypertens; 2002 Mar; 20(3):439-46. PubMed ID: 11875311
[TBL] [Abstract][Full Text] [Related]
11. Captopril ameliorates the decreased Na+,K(+)-ATPase activity in the retina of streptozotocin-induced diabetic rats.
Ottlecz A; Bensaoula T
Invest Ophthalmol Vis Sci; 1996 Jul; 37(8):1633-41. PubMed ID: 8675407
[TBL] [Abstract][Full Text] [Related]
12. Captopril inhibits capillary degeneration in the early stages of diabetic retinopathy.
Zhang JZ; Xi X; Gao L; Kern TS
Curr Eye Res; 2007 Oct; 32(10):883-9. PubMed ID: 17963108
[TBL] [Abstract][Full Text] [Related]
13. Plasma kallikrein mediates angiotensin II type 1 receptor-stimulated retinal vascular permeability.
Phipps JA; Clermont AC; Sinha S; Chilcote TJ; Bursell SE; Feener EP
Hypertension; 2009 Feb; 53(2):175-81. PubMed ID: 19124682
[TBL] [Abstract][Full Text] [Related]
14. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
[TBL] [Abstract][Full Text] [Related]
15. Anti-fibrogenic effects of captopril and candesartan cilexetil on the hepatic fibrosis development in rat. The effect of AT1-R blocker on the hepatic fibrosis.
Tuncer I; Ozbek H; Ugras S; Bayram I
Exp Toxicol Pathol; 2003 Sep; 55(2-3):159-66. PubMed ID: 14620537
[TBL] [Abstract][Full Text] [Related]
16. Candesartan cilexetil: an angiotensin II receptor blocker.
Stoukides CA; McVoy HJ; Kaul AF
Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
[TBL] [Abstract][Full Text] [Related]
17. Effects of candesartan on the renin system in conscious rats.
Wagner C; Kurtz A
J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S169-71. PubMed ID: 9892158
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of postischemic treatment with hypotensive doses of an angiotensin II receptor blocker on transient focal cerebral ischemia.
Fu H; Hosomi N; Pelisch N; Nakano D; Liu G; Ueno M; Miki T; Masugata H; Sueda Y; Itano T; Matsumoto M; Nishiyama A; Kohno M
J Hypertens; 2011 Nov; 29(11):2210-9. PubMed ID: 21934531
[TBL] [Abstract][Full Text] [Related]
19. Endothelin-3 regulation of retinal hemodynamics in nondiabetic and diabetic rats.
Mori F; King GL; Clermont AC; Bursell DK; Bursell SE
Invest Ophthalmol Vis Sci; 2000 Nov; 41(12):3955-62. PubMed ID: 11053299
[TBL] [Abstract][Full Text] [Related]
20. Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats.
Noda M; Fukuda R; Matsuo T; Ohta M; Nagano H; Imura Y; Nishikawa K; Shibouta Y
Kidney Int Suppl; 1997 Dec; 63():S136-9. PubMed ID: 9407442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
